18F-fluorodeoxyglucose positron emission tomography might be useful for diagnosis of hepatic amyloidosis

References

• ParkMAMuellerPSKyleRALarsonDRPlevakMFGertzMAPrimary (AL) hepatic amyloidosis: clinical features and natural history in 98 patientsMedicine (Baltimore)200382529129814530778
   PubMed Web of Science ®Google Scholar
• LevineRAAmyloid disease of the liver. Correlation of clinical, functional and morphologic features in forty-seven patientsAm J Med19623334935714464647
   PubMed Web of Science ®Google Scholar
• BuckFSKossMNHepatic amyloidosis: morphologic differences between systemic AL and AA typesHum Pathol19912299049071916751
   PubMed Web of Science ®Google Scholar
• UenishiTTeramuraKKitamuraMHyperkeratotic variant of porokeratosis Mibelli with dermal amyloid depositsJ Dermatol201037547547920536654
   PubMed Web of Science ®Google Scholar
• PambuccianSEHorydIDCawteTHuvosAGAmyloidoma of bone, a plasma cell/plasmacytoid neoplasm. Report of three cases and review of the literatureAm J Surg Pathol19972121791869042284
   PubMed Web of Science ®Google Scholar
• HachullaEJaninAFlipoRMLabial salivary gland biopsy is a reliable test for the diagnosis of primary and secondary amyloidosis. A prospective clinical and immunohistologic study in 59 patientsArthritis Rheum19933656916977683882
   PubMed Web of Science ®Google Scholar
• KawaguchiTSumidaYUmemuraATakeshi OkanoueGenetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in JapanesePLoS One201276e3832222719876
   PubMed Web of Science ®Google Scholar
• EbertECNagarMGastrointestinal manifestations of amyloidosisAm J Gastroenterol2008103377678718076735
   PubMed Web of Science ®Google Scholar
• KyleRAGertzMAPrimary systemic amyloidosis: clinical and laboratory features in 474 casesSemin Hematol199532145597878478
   PubMed Web of Science ®Google Scholar
• KyleRAGertzMAGreippPRA trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicineN Engl J Med199733617120212079110907
   PubMed Web of Science ®Google Scholar
• LevyMFrydCHEliakimMIntrahepatic obstructive jaundice due to amyloidosis of the liver. A case report and review of the literatureGastroenterology19716122342385314952
   PubMed Web of Science ®Google Scholar
• PetersRAKoukoulisGGimsonAPortmannBWestabyDWilliamsRPrimary amyloidosis and severe intrahepatic cholestatic jaundiceGut1994359132213257959246
   PubMed Web of Science ®Google Scholar
• GoenkaMKBhasinDKVasisthRKDhawanSHepatic amyloidosis presenting with severe intrahepatic cholestasisJ Clin Gastroenterol19962321341368877643
   PubMed Web of Science ®Google Scholar
• FerraroEMAlfelorFRLeeMPoonTTHepatic amyloidosis in an iv drug abuser detected by bone scintigraphyClin Nucl Med19871242742763581606
   PubMed Web of Science ®Google Scholar
• LomeñaFRosellóRPonsFAbnormal scintigraphic evolution in AA hepatic amyloidosisClin Nucl Med19881331941962838214
   PubMed Web of Science ®Google Scholar
• SuzukiKOkudaKYoshidaTKandaYFalse-positive liver scan in a patient with hepatic amyloidosis: case reportJ Nucl Med197617131321244444
   PubMed Web of Science ®Google Scholar
• SonYMChoiJYBakCH18F-FDG PET/CT in primary AL hepatic amyloidosis associated with multiple myelomaKorean J Radiol201112563463721927567
   PubMed Web of Science ®Google Scholar
• MekinianAJaccardASoussanMCentre de Référence des Amyloses immunoglobulinémiques et autres maladies liées aux dépots des immunoglobulines monoclonales18F-FDG PET/CT in patients with amyloid light-chain amyloidosis: case-series and literature reviewAmyloid2012192949822587492
   PubMed Web of Science ®Google Scholar
• LevyMPolliackALenderMEliakimMThe liver in amyloidosisDigestion197410140514847635
   PubMed Web of Science ®Google Scholar
• KitamuraYYokomoriHHepatic amyloidosis manifesting severe intrahepatic cholestasisIntern Med200544667567616020906
   PubMed Web of Science ®Google Scholar
• HoshiiYTakahashiMIshiharaTUchinoFImmunohistochemical classification of 140 autopsy cases with systemic amyloidosisPathol Int19944453523588044304
   PubMed Web of Science ®Google Scholar
• LachmannHJGallimoreRGillmoreJDOutcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapyBr J Haematol20031221788412823348
   PubMed Web of Science ®Google Scholar
• JoyTWangJHahnAHegeleRAAPOA1 related amyloidosis: a case report and literature reviewClin Biochem200336864164514636880
   PubMed Web of Science ®Google Scholar
• GertzMAKyleRAHepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patientsAm J Med198885173803389383
   PubMed Web of Science ®Google Scholar
• GertzMAComenzoRFalkRHDefinition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, April 18–22, 2004Am J Hematol200579431932816044444
   PubMed Web of Science ®Google Scholar
• SzturzPKyclováJMoulisMExtensive Al amyloidosis presenting with recurrent liver hemorrhage and hemoperitoneum: case report and literature reviewKlin Onkol2013261495223528174
   PubMedGoogle Scholar
• Loustaud-RattiVRCypierreARousseauANon-invasive detection of hepatic amyloidosis: FibroScan, a new toolAmyloid2011181192421219116
   PubMed Web of Science ®Google Scholar
• DustonMASkinnerMMeenanRFCohenASSensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosisArthritis Rheum198932182852912466
   PubMed Web of Science ®Google Scholar
• MainentiPPCantalupoTNicotraSSystemic amyloidosis: the CT sign of splenic hypoperfusionAmyloid200411428128215678766
   PubMed Web of Science ®Google Scholar
• MainentiPPCameraLNicotraSSplenic hypoperfusion as a sign of systemic amyloidosisAbdom Imaging200530676877216096868
   PubMedGoogle Scholar
• DhodapkarMVHusseinMARasmussenEUnited States Intergroup Trial Southwest Oncology GroupClinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628Blood2004104123520352615308571
   PubMed Web of Science ®Google Scholar
• PalladiniGPerfettiVObiciLAssociation of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantationBlood200410382936293815070667
   PubMed Web of Science ®Google Scholar
• PalladiniGPerfettiVPerliniSThe combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)Blood200510572949295115572585
   PubMed Web of Science ®Google Scholar
• DispenzieriALacyMQZeldenrustSRThe activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosisBlood2007109246547017008538
   PubMed Web of Science ®Google Scholar
• KastritisEAnagnostopoulosARoussouMTreatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasoneHaematologica200792101351135818024372
   PubMed Web of Science ®Google Scholar
• DispenzieriAKyleRALacyMQSuperior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control studyBlood2004103103960396314739213
   PubMed Web of Science ®Google Scholar